Hepatocellular cancer treatment guidelines
- Verslype 1,2O.
- cancer Hepatocellular
Males and females at least 18 years of age. HCC is advanced, ie, treatment-refractory or metastatic, and no standard therapies are expected to be curative.
Receipt of 1 previous systemic drug therapy for at least 3 weeks and withdrawal from treatment due either to intolerability or to radiographic disease progression. Prior systemic treatment hepatocellular cancer treatment guidelines discontinued for at least 2 weeks prior to the Baseline Visit. Exclusion Criteria: 1. Locoregional treatment within 4 weeks prior to the Baseline Visit.
Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit. Use of any investigational agent within 4 weeks prior to the Baseline Visit.
Child-Pugh Class A or C cirrhosis, or hepatic encephalopathy. Occurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion within 4 weeks prior to the Baseline Visit. Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.
Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness. Liver transplant. Active malignancy other than HCC.
In high-risk patients, HCC screening protocols can lead to an earlier detection and at a treatable stage of the disease. Keywords Multiparametric Magnetic Resonance Imaging, diagnosis, hepatocellular carcinoma Rezumat Carcinomul hepatocelular CHC este cea mai frecventă tumoră malignă primară a ficatului, asociată frecvent cu ciroza, cu o incidenţă crescândă la nivel mondial. Protocoalele de screening al CHC la pacienţii cu risc crescut pot duce la detectarea mai precoce şi într-un stadiu tratabil al bolii.
Pregnant or lactating female. Interested in learning more?